{
 "name": "安立璽榮-KY",
 "slug": "tw-7871",
 "aliases": [
  "安立璽榮醫藥股份有限公司",
  "Elixiron-KY",
  "7871"
 ],
 "ticker": "7871",
 "industry": "生技醫療業",
 "website": "https://elixiron.com",
 "summary": "安立璽榮-KY（7871）是興櫃的生技醫療類股公司，2017 年成立，2026 年登錄興櫃。基本資料取自臺灣證券交易所／證券櫃檯買賣中心公開資料；重大訊息見 https://drugnews.com.tw/filings/ 。",
 "facts": [
  {
   "claim": "公司全名",
   "value": "安立璽榮醫藥股份有限公司",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "英文簡稱",
   "value": "Elixiron-KY",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "產業類別",
   "value": "生技醫療業",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "掛牌市場",
   "value": "證券櫃檯買賣中心興櫃",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "登錄興櫃日期",
   "value": "2026-01-13",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "成立日期",
   "value": "2017-01-13",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "董事長",
   "value": "陳泓愷",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "總經理",
   "value": "陳泓愷",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "實收資本額",
   "value": 1342781940,
   "unit": "新台幣元",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "簽證會計師事務所",
   "value": "資誠聯合會計師事務所",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "公司網址",
   "value": "https://elixiron.com",
   "unit": "",
   "as_of": "2026-10-21",
   "source": "https://www.tpex.org.tw/openapi/v1/mopsfin_t187ap03_R"
  },
  {
   "claim": "管線：EI-1071（enrupatinib；第二期概念驗證試驗）",
   "value": "阿茲海默症｜第二期概念驗證試驗已完成｜台灣",
   "unit": "",
   "as_of": "2026-09-23",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT06745583",
   "note": "NCT06745583；Last Update Posted 2026-09-23；Overall Status=COMPLETED，Study Completion ACTUAL=2026-05-06。單一試驗完成不等於整體藥物開發或上市核准。 2026-09-18 MOPS公告同一NCT試驗預定收案15人修訂為7人獲TFDA同意，並非新增二期試驗。另有獨立食物影響一期試驗，見本檔其他fact。"
  },
  {
   "claim": "管線：EI-001（indemakitug）",
   "value": "非節段型白斑症｜第二期臨床試驗招募中｜美國、台灣",
   "unit": "",
   "as_of": "2026-06-05",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07223229",
   "note": "NCT07223229；Last Update Posted 2026-06-05；招募狀態及地區取自登錄。學名另見2026-06-04公司法說簡報第5、21頁。"
  },
  {
   "claim": "催化劑：EI-001",
   "value": "白斑症第二期試驗預估主要完成日｜2026-12-31｜已公告",
   "unit": "",
   "as_of": "2026-06-05",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07223229",
   "note": "NCT07223229；Primary Completion ESTIMATED，不是保證結果公布日。"
  },
  {
   "claim": "催化劑：EI-001",
   "value": "白斑症第二期試驗預估試驗完成日｜2027-09-30｜已公告",
   "unit": "",
   "as_of": "2026-06-05",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07223229",
   "note": "NCT07223229；Study Completion ESTIMATED；與主要完成日不同。"
  },
  {
   "claim": "催化劑：EI-001",
   "value": "白斑症初步臨床數據｜2027（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-06-04",
   "source": "https://elixiron.com/upload/2026_06_16_1605311.pdf",
   "note": "公司法說第25頁明載Preliminary clinical data expected in 2027；未加造季度或日。"
  },
  {
   "claim": "管線：EI-1071（enrupatinib；食物影響試驗）",
   "value": "阿茲海默症藥物之食物影響評估｜第一期臨床試驗獲TFDA核准執行｜台灣",
   "unit": "",
   "as_of": "2026-09-29",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "查詢7871、115年度、全年度、序號1。發言日期2026-09-29 00:31:36；主旨：代重要子公司安立璽榮生醫股份有限公司公告，用於治療阿茲海默症之新藥EI-1071，獲台灣衛生福利部食品藥物管理署(TFDA)核准執行食物影響第一期臨床試驗。事實發生日2026-09-24；as_of採發布日。公告明載此一期與既有二期目的、設計及族群不同，分別執行與判讀。新試驗NCT編號公告尚未提供。"
  },
  {
   "claim": "催化劑：EI-1071",
   "value": "食物影響第一期試驗完成收案｜2027（公司預估）｜已公告",
   "unit": "",
   "as_of": "2026-09-29",
   "source": "https://mops.twse.com.tw/mops/#/web/t05st01",
   "note": "查詢7871、115年度、全年度、序號1。發言日期2026-09-29 00:31:36；主旨：代重要子公司安立璽榮生醫股份有限公司公告，用於治療阿茲海默症之新藥EI-1071，獲台灣衛生福利部食品藥物管理署(TFDA)核准執行食物影響第一期臨床試驗。第6(1)項預計2027年完成收案，未給季度；實際依執行、分析及主管機關溝通而定。"
  },
  {
   "claim": "管線：EI-012（PLT012；anti-CD36單株抗體）",
   "value": "晚期實體腫瘤｜第一期臨床試驗招募中｜美國",
   "unit": "",
   "as_of": "2026-07-07",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07337525",
   "note": "NCT07337525；Last Update Posted 2026-07-07；PHASE1、RECRUITING。公司2026-06-04簡報第30頁列EI-012=PLT-012；MOPS 2026-03-13公告授權方Pilatus已完成首例給藥。"
  },
  {
   "claim": "催化劑：EI-012",
   "value": "PLT012第一期試驗預估主要完成月份｜2027-09｜已公告",
   "unit": "",
   "as_of": "2026-07-07",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07337525",
   "note": "NCT07337525；Primary Completion ESTIMATED僅到月份，未補造日期。"
  },
  {
   "claim": "催化劑：EI-012",
   "value": "PLT012第一期試驗預估試驗完成月份｜2028-01｜已公告",
   "unit": "",
   "as_of": "2026-07-07",
   "source": "https://clinicaltrials.gov/api/v2/studies/NCT07337525",
   "note": "NCT07337525；Study Completion ESTIMATED僅到月份，未補造日期。"
  }
 ],
 "provided_by": "public_sources",
 "verified_at": "2026-10-22",
 "url": "https://drugnews.com.tw/companies/tw-7871.json",
 "generated_at": "2026-10-23T11:48:56.615Z"
}